Strontium Ranelate Suppliers & Bulk Manufacturers
Available Forms: Sachet
Available Strengths: 2 g
Reference Brands: Osseor (EU/UK)
Category:
Osteoporosis
Strontium Ranelate is available in Sachet
and strengths such as 2 g.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Strontium Ranelate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Strontium Ranelate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Strontium ranelate is a medication used for the treatment of osteoporosis, a condition that weakens bones and increases the risk of fractures. It is a strontium(II) salt of ranelic acid and has been marketed in several countries under brand names such as Protelos and Protos. The medicine is primarily prescribed to improve bone strength in patients who are at high risk of bone fractures, particularly postmenopausal women with osteoporosis.
One of the distinctive features of strontium ranelate is its dual mechanism of action on bone metabolism. Unlike many osteoporosis treatments that mainly focus on reducing bone loss, strontium ranelate both stimulates the formation of new bone and decreases the breakdown of existing bone. It works by increasing the activity of osteoblasts, the cells responsible for building bone, while simultaneously reducing the activity of osteoclasts, the cells that break down bone tissue. Because of this combined effect, it is often described as a dual action bone agent (DABA).
In addition to its role in osteoporosis management, some studies have suggested that strontium ranelate may help slow the progression of knee osteoarthritis by supporting bone and joint structure. However, its use is typically guided by medical evaluation and regulatory recommendations in different countries.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing